The pharmaceutical company’s consolidated EPS rose to Tk31.24 in FY26 from Tk27.04 a year earlier, while the proposed investment will support modernisation and expansion.
TBS Report
26 October, 2026, 05:10 pm
Last modified: 26 October, 2026, 05:12 pm
Square Pharmaceuticals PLC has recommended a 130% cash dividend for the financial year ended 30 June 2026 and approved a Tk725 crore investment plan to modernise and expand its business.
The company disclosed the decisions following a board meeting held today (26 October).
The board recommended the dividend for the 2025-26 financial year. The company has scheduled its annual general meeting (AGM) for 15 December to seek shareholders' approval, with 16 November set as the record date for determining eligible shareholders.
The board also approved Tk725 crore for balancing, modernisation, rehabilitation and expansion (BMRE), capital machinery and land acquisitions to support future business growth.
Square Pharma's consolidated earnings per share (EPS) rose to Tk31.24 in FY26 from Tk27.04 in the previous financial year. On a standalone basis, EPS increased to Tk18.43 from Tk16.63.
The company's consolidated net asset value (NAV) per share stood at Tk178.99 as of 30 June 2026, up from Tk157.88 a year earlier.
However, consolidated net operating cash flow per share (NOCFPS) declined to Tk18.65 in FY26 from Tk19.52 in FY25.